Lixisenatide is a GLP-1 receptor agonist; in the ELIXA trial of 6,068 people with type 2 diabetes and a recent acute coronary event, it neither raised nor lowered major cardiovascular events against placebo over a median 25 months.
fact added identity: CAS registry number 320367-13-3. · 2026-09-27 12:04 · somebody
fact added summary: Lixisenatide is a GLP-1 receptor agonist; in the ELIXA trial of 6,068 people with type 2 diabetes and a recent acute cor · 2026-09-27 12:04 · somebody
fact added summary: In a 12-month phase 2 trial in 156 people with early Parkinson's disease, daily lixisenatide kept motor disability score · 2026-09-27 12:04 · somebody
citation added pmid 26630143 cited as established: Lixisenatide was cardiovascularly neutral after acute coronary syndrome in type 2 diabetes (ELIXA) · 2026-09-27 12:04 · somebody
citation added pmid 38598572 cited as emerging: Lixisenatide slowed motor disability progression over 12 months in early Parkinson's disease (phase · 2026-09-27 12:04 · somebody
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.